[Progressive multifocal leukoencephalopathy in a patient with multiple myeloma]

Cecilie Balslev Willert1, Frederik Neess Engsig, Helle Wulf Eskildsen

  • 1Dagmarsgade 10, 3. th., 2200 København N. ceciliebwi@gmail.com.

Ugeskrift for Laeger
|December 16, 2014
PubMed

Insights

Progressive multifocal leukoencephalopathy (PML), a rare brain disease caused by John Cunningham virus reactivation, can occur in immunocompromised patients. This case highlights PML in a multiple myeloma patient treated with chemotherapy, emphasizing its importance in diagnosing neurological symptoms.

Area of Science:

  • Neuroimmunology
  • Neurology
  • Oncology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a rare, severe demyelinating disease of the central nervous system.
  • PML is caused by the reactivation of the John Cunningham virus (JCV).
  • It most commonly affects individuals with HIV/AIDS but can also occur in those with iatrogenic immunodeficiency.

Observation:

  • A patient with multiple myeloma and cardiac amyloidosis developed PML.
  • The patient had received multiple chemotherapeutic agents.
  • This presentation occurred in the context of iatrogenic immunodeficiency.

Findings:

  • This case report details a rare instance of PML in a patient with multiple myeloma and cardiac amyloidosis.
  • The development of PML was associated with chemotherapy treatment.
  • The patient exhibited diffuse neurological symptoms.

Implications:

  • Highlights the importance of considering PML in the differential diagnosis of neurological symptoms in immunocompromised patients.
  • Underscores the potential risk of PML in patients undergoing chemotherapy, particularly those with underlying conditions like multiple myeloma.
  • Emphasizes the need for vigilance in recognizing PML in diverse immunocompromised populations beyond HIV/AIDS.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
4
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
8.0K
Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
4
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
18